# Silence Therapeutics plc (SLN) · Edgar & Edgarette company card

> Silence Therapeutics (SLN) saw revenue fall 98.7% in FY2025 to $1 million, operating margin -16293% against a -3.8% median for pharmaceutical preparations, equity 47.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1479615 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/SLN) · [JSON](https://www.pops4.com/boards/company/SLN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $559,000 |
| Revenue growth, 1 year | -98.7% |
| Revenue growth per year | -70.4% |
| Operating margin | -16292.8% (prior year -146.4%) |
| Net margin | -15851.9% |
| Operating cash flow | −$62M |
| Capital spending | $55,000 |
| Free cash flow | −$62M |
| Cash | $11M |
| Long-term debt | — |
| Total assets | $131M |
| Total equity | $62M |
| Equity ÷ assets | 47.4% |
| Return on equity | -142.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -12.42 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$62.3M in FY2025); operating loss: a margin of -16292.8% in FY2025; revenue is hard to predict: its 80% range is ±47%

## Edgarette's reading

Exposure: revenue $559K (FY2025). Experience: revenue down 98.7% on the year, down 70.4% a year over 3 years; operating margin -16292.8%, down from -146.4%. Soundness: equity 47.4% of assets, return on equity -142.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $51K and $141K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $47K to $151K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -16292.8% against a -3.8% median; growth -98.7% against 13.7%.

Range logged 2026-10-20, receipt 6041d510711d4f12, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2025-12-22 ([filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312525327575/0001193125-25-327575-index.htm))

## Recent filings

- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526458896/0001193125-26-458896-index.htm)
- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/0001193125-26-457060-index.htm)
- 8-K · filed 2026-10-19 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526424695/0001193125-26-424695-index.htm)
- 8-K · filed 2026-08-12 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526347196/0001193125-26-347196-index.htm)
- 8-K · filed 2026-08-10 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/0001193125-26-341293-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341248/0001193125-26-341248-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001479615.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1479615

## Cite

POPS4, Edgar & Edgarette: Silence Therapeutics plc (SLN) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/SLN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

